SCHEMBL5545647

SCHEMBL5545647

O=c1[nH]c2ccccc2n(CCN2CCOCC2)c1=O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 6/20 0.55
KDM4E B2RXH2 3/20 0.50
GRIA1 P42261 2/20 0.50
GRIA2 P42262 2/20 0.50
GRIA3 P42263 2/20 0.50
GRIA4 P48058 2/20 0.50
GAA P10253 2/20 0.50
HSD17B10 Q99714 1/20 0.50
PARP1 P09874 1/20 0.49
P2RX7 Q99572 1/20 0.49
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GLA P06280 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5549618 0.87 LMNA (0.61) HTR7KDM4EGRIA1GRIA2GRIA3
SCHEMBL739228 0.86 HTR7 (0.73) HTR7P2RX7LMNAMEN1ALDH1A1
Hydrochloric Acid SCHEMBL9725420 0.84 HTR7 (0.71) HTR7P2RX7LMNAMEN1ALDH1A1
SCHEMBL10723261 0.80 ALDH1A1 (0.55) HTR7KDM4EMEN1ALDH1A1MAPT
SCHEMBL26133881 0.80 HTR7 (0.51) HTR7KDM4EGAAP2RX7LMNA
SCHEMBL4037944 0.80 LMNA (0.74) HTR7P2RX7LMNAMEN1PKM
SCHEMBL8343164 0.79 KCNH2 (0.45) PARP1MEN1KMT2A
SCHEMBL24335550 0.76 GRIA1 (0.57) KDM4EGRIA1GRIA2GRIA3GRIA4
SCHEMBL29580203 0.76 GRIA1 (0.57) KDM4EGRIA1GRIA2GRIA3GRIA4
SCHEMBL30898291 0.75 GRIA1 (0.56) GRIA1GRIA2GRIA3GRIA4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1711184-B1 (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA NV (BE) 2007-07-18 EP disclosed
EP-1711184-B1 (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA NV (BE) 2007-07-18 EP disclosed
US-20050148586-A1 Quinoxalinones JANSSEN PHARMACEUTICA, N.V. (BE) 2005-07-07 US disclosed
US-5075304-A Nervous system disorders NOVO NORDISK A/S (DK) 1991-12-24 US disclosed
EP-0344943-A1 Imidazoquinoxaline compounds and their preparation and use NOVO NORDISK A/S (DK) 1989-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148586-A1 Quinoxalinones SLC5A2, GPR119, GLS2 HTR7 499/4885KDM4E 1657/4885GRIA1 2287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.